Drug Information

Drug General Information
Drug ID
D0O8KX
Former ID
DNCL002048
Drug Name
Reslizumab
Drug Type
Monoclonal antibody
Indication Severe asthma [ICD9: 493; ICD10:J45] Approved [889440]
Eosinophilic asthma [ICD9: 493; ICD10:J45] Phase 3 [523350], [542965]
Asthma; Eosinophilic esophagitis; Severe asthma; Loiasis [ICD10:J45, K200] Phase 2 [889348], [889350], [889358], [889427], [889434]
Company
Teva
Target and Pathway
Target(s) Interleukin-5 Target Info Modulator [889443]
KEGG Pathway Cytokine-cytokine receptor interaction
Jak-STAT signaling pathway
Hematopoietic cell lineage
T cell receptor signaling pathway
Fc epsilon RI signaling pathway
Intestinal immune network for IgA production
Asthma
Autoimmune thyroid disease
Inflammatory bowel disease (IBD)
Allograft rejection
NetPath Pathway TCR Signaling Pathway
IL2 Signaling Pathway
RANKL Signaling Pathway
PANTHER Pathway Interleukin signaling pathway
Pathway Interaction Database Regulation of nuclear SMAD2/3 signaling
IL4-mediated signaling events
Calcineurin-regulated NFAT-dependent transcription in lymphocytes
Glucocorticoid receptor regulatory network
IL5-mediated signaling events
AP-1 transcription factor network
PathWhiz Pathway Fc Epsilon Receptor I Signaling in Mast Cells
Reactome GPVI-mediated activation cascade
G beta:gamma signalling through PI3Kgamma
Interleukin-3, 5 and GM-CSF signaling
RAF/MAP kinase cascade
Interleukin receptor SHC signaling
WikiPathways Cytokines and Inflammatory Response
Inflammatory Response Pathway
Hematopoietic Stem Cell Differentiation
Interleukin-2 signaling
Allograft Rejection
Interleukin-3, 5 and GM-CSF signaling
References
Ref 523350ClinicalTrials.gov (NCT01290887) Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma. U.S. National Institutes of Health.
Ref 542965(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8091).
Ref 889348ClinicalTrials.gov (NCT00538434) Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years
Ref 889350ClinicalTrials.gov (NCT00587288) Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled Asthma
Ref 889358ClinicalTrials.gov (NCT01111305) Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis
Ref 889427ClinicalTrials.gov (NCT02947945) Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study
Ref 889434ClinicalTrials.gov (NCT03074942) Reslizumab in Patients With Severe Asthma Who Failed to Respond to Omalizumab
Ref 8894402016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. doi: 10.1038/nrd.2017.14.
Ref 889443The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. doi: 10.1038/nrd3792.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.